- News & Media
Tikcro’s approach is based on 3D (three dimensional) antigens which are designed to generate blocking antibodies. This approach aims to offer superior results in targeting discontinued epitopes. Tikcro plans to identify novel antibodies to validated immune targets and bring next-generation antibodies that increase the response rate of such treatments and decrease side effects by exclusively binding to the receptor or ligand of choice.
We have identified promising new antibody targets in the pathways of CTLA4 and PD1 receptors and their ligands, and are promoting further immunization and selection process to generate such antibodies.
Tikcro, for the first time, successfully uses a novel technology of 3D designed antigens, which, post immunization of an animal, (rodent or the like), results with specific blocking antibodies.